"I may have been swayed if this represented a major advance in the field," said panelist Walter Dunn, MD, PhD, of the ...

Following the FDA ODAC's vote against belantamab mafodotin-based combinations in relapsed/refractory multiple myeloma, George Mulligan, PhD, provides insight into the agent's potential path foward.

Overview of Nanotechnology Drug Delivery MarketThe global Nanotechnology Drug Delivery Market is valued at USD 97.98 Billion ...

Peter Mac researchers have discovered a powerful new drug combination that could offer hope to children and adults with ...

Which drug combinations are best for prevention of nausea and vomiting caused by chemotherapy in adults with cancer?

MIT researchers have developed a new theoretical framework for studying the mechanisms of treatment interactions. Their ...

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

Verastem's FDA approval for KRAS-mutant LGSOC, strong pipeline, and catalysts signal growth potential. Click here to read an ...

Novartis AG NVS, a Swiss pharma giant, is scheduled to report second-quarter 2025 results on July 17. The Zacks Consensus Estimate for revenues is pegged at $14.04 billion, while the same for earnings ...

Nurix Therapeutics shows strong BTK degrader data and key pharma ties, with risks but solid long-term potential. Find out why ...